BusinessKura Oncology Announces Presentation of Preliminary Clinical Data for Tipifarnib in HRAS Mutant Squamous Cell Carcinomas of the Head and Neck at TAT 2017By Nasdaq OMXFeb 27, 2017, 12:30 PM UTC
BusinessKura Oncology to Participate in Three Upcoming Investor ConferencesBy Nasdaq OMXFeb 9, 2017, 9:07 PM UTC
BusinessKura Oncology to Participate in Three Upcoming Investor ConferencesBy Nasdaq OMXFeb 9, 2017, 9:07 PM UTC
BusinessKura Oncology to Participate in Three Upcoming Investor ConferencesBy Nasdaq OMXFeb 9, 2017, 9:07 PM UTC
BusinessKura Oncology Receives FDA Clearance to Proceed with Clinical Trial for ERK Inhibitor KO-947 and Nominates KO-539 as Development Candidate for Menin-MLL Inhibitor ProgramBy Nasdaq OMXJan 4, 2017, 12:30 PM UTC
BusinessKura Oncology Presents Preclinical Data on KO-947 and Menin-MLL Inhibitor Program at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsBy Nasdaq OMXDec 1, 2016, 12:30 PM UTC
BusinessKura Oncology to Present Preclinical Data on Pipeline Programs at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsBy Nasdaq OMXNov 15, 2016, 12:30 PM UTC
BusinessKura Oncology Reports Third Quarter 2016 Financial ResultsBy Nasdaq OMXNov 7, 2016, 9:05 PM UTC
